Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02072603 · ClinicalTrials.gov registry record · NA
Evaluation of the HITSystem to Improve Early Infant Diagnosis Outcomes in Kenya
A NA study of HIV, sponsored by Sarah Kessler, PhD, MPH.
- Completed
- Registry status
- NA
- Development phase
- 1,815
- Enrollment target
- 2
- Study locations
NCT02072603: Completed NA study of HIV, sponsored by Sarah Kessler, PhD, MPH.
NCT02072603 is a NA study of HIV that has completed, run by Sarah Kessler, PhD, MPH. The registered enrollment target is 1,815 participants, above the 434-participant average among 303 other HIV trials with a reported enrollment target (318% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02072603, a NA study of HIV, has completed, sponsored by Sarah Kessler, PhD, MPH.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,815 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine the effectiveness of the HITSystem in maximizing early infant diagnosis (EID) service utilization for HIV-exposed infants and early antiretroviral therapy (ART) initiation for infants diagnosed with HIV.
Primary Outcome
An aggregate measure of complete EID retention will be calculated (y/n) for each infant. Complete EID retention indicates the infant received all indicated services along the EID cascade as detailed below in the 8 critical interventions for EID of HIV. The proportion of HIV-exposed infants with complete EID retention will be compared between groups. 1. Initiation of OI prophylaxis. 2. Collect dried blood spot (DBS) for PCR test. 3. Receipt of DBS at lab. 4. Return of PCR results from lab. 5. No
Conditions Studied
Interventions
- OTHER Standard of Care
- OTHER HITSystem
Study Locations (2)
Kansas
- University of Kansas Medical Center - Kansas City
Other
- Kenyan Medical Research Institute - Nairobi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,815 participants |
| Start Date | 2014-03-30 |
| Est. Completion | 2020-04-30 |
| Phase | NA |
What the finished NCT02072603 record still lists
NCT02072603 is an interventional study that assigns participants to a tested intervention. Its 1,815 participants enrollment target places it among the larger protocols in the corpus, above the 434-participant average among 303 other HIV trials with a reported enrollment target (318% higher).
The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.
NCT02072603 reports a single indexed study location in Kansas, Other.
Frequently Asked Questions
What is clinical trial NCT02072603 about?
NCT02072603 is a clinical study titled "Evaluation of the HITSystem to Improve Early Infant Diagnosis Outcomes in Kenya". The purpose of this study is to determine the effectiveness of the HITSystem in maximizing early infant diagnosis (EID) service utilization for HIV-exposed infants and early antiretroviral therapy (ART) initiation for infants diagnosed with HIV.
What is the current status of trial NCT02072603?
This trial is currently completed. It is a NA study. The enrollment target is 1,815 participants. The study started on 2014-03-30. Estimated completion is 2020-04-30.
What conditions does trial NCT02072603 study?
This clinical trial studies the following conditions: HIV.
What interventions are being tested in trial NCT02072603?
The interventions under investigation include: Standard of Care (OTHER), HITSystem (OTHER).
Who is sponsoring clinical trial NCT02072603?
This trial is sponsored by Sarah Kessler, PhD, MPH, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02072603 being conducted?
This trial has 2 study locations across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02072603's enrollment target sits among peer trials
1,815 11th of 303 higher than 293 of 303 other HIV trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
1MoreStep: An Intervention to Increase HIV Care Engagement and Reduce Intimate Partner Violence Among Black Women Living With HIV
RECRUITING · NA
-
Implementation Trial to Evaluate a Population Health Combination Intervention to Meet HIV Testing, Linkage, and Viral Suppression Goals in Alabama
RECRUITING · NA
-
ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services
RECRUITING · NA
-
Assessing Peer Support for Physical Activity in Women With HIV and Hypertension
RECRUITING · NA
-
Open Trial of Trauma-focused Psychodynamic Psychotherapy for People Living With HIV and PTSD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05897788 · 1,808 participants · NA
Text-Messaging Telehealth and Contingency Management for Opioid Use Disorder Treatment Engagement
- NCT05935007 · 1,805 participants
Aveir DR Real-World Evidence Post-Approval Study
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI